TBPH Theravance Biopharma Inc

Price (delayed)

$8.97

Market cap

$682.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$1.26B

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
Theravance Biopharma's EPS has surged by 53% YoY and by 29% QoQ
The net income has grown by 47% YoY and by 27% from the previous quarter
TBPH's equity is up by 6% year-on-year but it is down by 3.8% since the previous quarter
TBPH's revenue is down by 18% year-on-year
The gross profit has contracted by 18% YoY

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
76.12M
Market cap
$682.76M
Enterprise value
$1.26B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
12.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.23
Earnings
Revenue
$54.25M
EBIT
-$99.11M
EBITDA
-$90.21M
Free cash flow
-$164.1M
Per share
EPS
-$2.03
Free cash flow per share
-$2.18
Book value per share
-$4.71
Revenue per share
$0.72
TBVPS
$4.72
Balance sheet
Total assets
$355.36M
Total liabilities
$706.81M
Debt
$672.95M
Equity
-$351.45M
Working capital
$160.44M
Liquidity
Debt to equity
-1.91
Current ratio
4.63
Quick ratio
4.44
Net debt/EBITDA
-6.4
Margins
EBITDA margin
-166.3%
Gross margin
100%
Net margin
-268.6%
Operating margin
-391.5%
Efficiency
Return on assets
-37.3%
Return on equity
N/A
Return on invested capital
-11.3%
Return on capital employed
-31.9%
Return on sales
-182.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
1.59%
1 week
3.22%
1 month
-0.88%
1 year
-47.54%
YTD
-18.82%
QTD
-6.17%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$54.25M
Gross profit
$54.25M
Operating income
-$212.39M
Net income
-$145.69M
Gross margin
100%
Net margin
-268.6%
The net income has grown by 47% YoY and by 27% from the previous quarter
Theravance Biopharma's net margin has increased by 35% YoY and by 26% QoQ
The operating income is up by 31% YoY and by 18% QoQ
TBPH's revenue is down by 18% year-on-year

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
12.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.23
Theravance Biopharma's EPS has surged by 53% YoY and by 29% QoQ
TBPH's equity is up by 6% year-on-year but it is down by 3.8% since the previous quarter
The P/S is 61% lower than the 5-year quarterly average of 31.3 and 4.3% lower than the last 4 quarters average of 12.8
TBPH's revenue is down by 18% year-on-year

Efficiency

How efficient is Theravance Biopharma business performance
The ROIC has soared by 55% YoY and by 36% from the previous quarter
Theravance Biopharma's return on sales has increased by 49% YoY and by 34% QoQ
The company's return on assets rose by 35% YoY and by 26% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 50% less than its total liabilities
The company's quick ratio rose by 45% YoY and by 12% QoQ
TBPH's current ratio is up by 37% year-on-year and by 9% since the previous quarter
TBPH's equity is up by 6% year-on-year but it is down by 3.8% since the previous quarter
The debt to equity fell by 6% YoY but it rose by 3.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.